Lucid Diagnostics Inc. Chooses Lake Forest as the Home of its New Test Center.

Lucid Diagnostics Inc. has chosen Lake Forest as the home of its new test center. The new test center is part of the second stage of Lucid’s Test Center program, which aims to grow and expand the organization into new metropolitan areas. 

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.

The test centers are staffed with Lucid-employed nurse practitioners who use EsoCheck to conduct a brief and non-invasive collection of surface esophageal cells from patients with GERD. These tests are sent to LucidDx Labs for EsoGuard testing and detect esophageal precancer before it progresses to deadly esophageal cancer. 

Lucid estimates that a single nurse practitioner can perform up to twenty EsoCheck procedures per day. Lucid believes EsoGuard is the first and only commercially available test capable of serving as a widespread tool to prevent esophageal cancer deaths, through early precancer detection in at-risk GERD patients.

To read more, click here.